tbuckley/cabot-search huggingface dataset:
THU0094 Impact of Biologic Discontinuation in Patients with Rheumatoid Arthritis: Observation from the Corrona Registry
Authors: D.A. Pappas, G.W. Reed, Y. Bao, S. Grant, V. Garg
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Biologic agents are effective therapies for rheumatoid arthritis (RA). It has been suggested that biologic taper and discontinuation may be a viable option for a subset of RA patients whose disease activity is in control. <h3>Objectives</h3> The objective of this study was to describe the outcomes of biologic withdrawal in RA in the real world setting. <h3>Methods</h3> Data from the Corrona registry were used. RA patients who discontinued biologic therapies after ≥1 year of continuous use, and who had no additional biologic use for the subsequent 12 months were included. Disease activity were evaluated at baseline (time of biologic discontinuation), 3, 6 and 12 months post biologic discontinuation. The percentage of patients who had at least 1 flare (i.e. an increase in Clinical Disease Activity Index (CDAI) by ≥16.11, 2) off biologic therapy was assessed. <h3>Results</h3> Of the 120 included patients: 97 (80.8%) were female; age (mean ± SD) was 58.7±12.5 years, CDAI was 15.2±15.1, ESR was 48.7±34.3, CRP was 9.1±10.2 and HAQ 1.0±0.7, all at baseline. After biologic discontinuation, 8.3% of patients had at least 1 flare by 3 months, 30% by 6 months and 41.7% by 12 months. <h3>Conclusions</h3> In the current study using data from Corrona, biologic discontinuation in RA was associated with flares whose rates increase over time. <h3>References</h3> Yoshida et al. Annals of the rheumatic diseases (2013). Ranganath, et al. Annals of the rheumatic diseases (2007). <h3>Acknowledgements</h3> The Corrona, LLC. RA registry has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Astra Zeneca, BMS, Genentech, Horizon Pharma USA, Janssen, Eli Lilly, Novartis, Pfizer, and UCB. The design, study conduct, and financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. <h3>Disclosure of Interest</h3> D. Pappas Employee of: Corrona, LLC., Paid instructor for: Novartis, G. Reed Employee of: Corrona, LLC., Y. Bao Shareholder of: AbbVie, Inc., Employee of: AbbVie, Inc., S. Grant Employee of: Fred Hutchinson Cancer Center, V. Garg Shareholder of: AbbVie, Inc., Employee of: AbbVie, Inc.
New Antimalarial Drugs
Authors: P Ambroise-Thomas
Journal: New England Journal of Medicine (1946)

Resistance of Plasmodia to available antimalarials is becoming very frequent. Discovering new drugs in this field is therefore a health priority. Only two new antimalarials appeared in the last few years: artemether IM (Paluther) for the treatment of severe malaria and a chloroquine-proguanil combination (Savarine) for the malarial chemoprophylaxis. Several other new molecules are under investigation. Only a few of them result from a targeted pharmacological research. On the other hand, the clinical and biological evaluation of new antimalarials is often conducted without respect of the international industrial guidelines and will probably fail to offer all the guarantees of efficacy and safety required for registration in western countries.
SAT0263 The Prevalence of Vertebral Fractures in Spondyloarthropathies: Relation to Disease Characteristics, Bone Mineral Density, Syndesmophytes and History of Back Pain and Trauma
Authors: P. Geusens, L. De Winter, D. Quaden, J. Vanhoof, D. Vosse, V. Somers
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> An increased risk of vertebral fracture (VF) is one of the extra-articular manifestations of spondyloarthropathies (SpA). The prevalence of moderate/severe radiographic vertebral fractures in SpA in daily practice is unknown until imaging of the full spine is available, as most VFs do not present with the clinical signs and symptoms of an acute fracture. <h3>Objectives</h3> The primary aim is to investigate the prevalence of VFs in SpA and the relation to clinical disease parameters. <h3>Methods</h3> We evaluated the prevalence of VFs (&gt;25% loss in height) on available radiographs of the thoracic and lumbar spine in 390 consecutive SpA patients in daily practice and their association with disease characteristics, bone mineral density (BMD), the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) and history of trauma. <h3>Results</h3> Forty-eight patients (12.3%) had a VF, of whom 56.3% were men, 44.7% had multiple VFs, and 93.8% of VFs were located in the thoracic spine. Compared to patients without VF, patients with a VF were older (52.4 vs. 47.3 years, p&lt;0.01, range 25-84 years), had a marginally lower femoral neck T-score (-1.0 vs. -0.7, p=0.06), more peripheral joint disease (4.4 vs. 3.5, p&lt;0.05) and a higher mSASSS (11.8 vs. 7.0, p&lt;0.05). Of patients with a VF, 14.6% had a history of trauma with acute back pain (p&lt;0.01 vs. no VF). <h3>Conclusions</h3> Moderate to severe vertebral fractures are found in more than 10% of SpA patients, already from the age of 25 years on. Most VFs are located in the thoracic region, are related to low femoral neck BMD and to stiffening of the spine, and are only in one out of six patients related to trauma history. <h3>Disclosure of Interest</h3> None declared
Cell Junctions
Authors: Ronald S. Weinstein, N. Scott McNutt
Journal: New England Journal of Medicine (1972)

CELLS interact with each other at short range to form coherent and metabolically Cooperative tissues. An important aspect to cell-to-cell interactions is the formation of specialized junctions at the surfaces of neighboring cells. Alterations in cell junctions may account for some important pathophysiologic phenomena. In this short review, we shall attempt to outline the major types of cell junctions found in vertebrates and mention some of their known functions. Owing to rapid changes both in terminology and in functional concepts, a casual reading of the literature on cell junctions may be confusing because the nomenclature for junctions has not been . . .
Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania
Authors: S L McElroy, P E Keck, H G Pope, J I Hudson, G L Faedda, A C Swann
Journal: American Journal of Psychiatry (1992)

The authors reviewed available evidence regarding the status of dysphoric or mixed mania as a distinct clinical state and formulated operational criteria for its diagnosis.Studies of dysphoric mania or hypomania in patients with bipolar disorder were analyzed with regard to clinical characteristics, prevalence, demographic features, course of illness, outcome, family history, associated conditions, biological tests, and response to biological treatment.Although some studies suggest that dysphoric and nondysphoric mania are similar conditions, others suggest that, compared with nondysphoric mania, dysphoric mania may be more severe; more likely to occur in women; more likely to be associated with suicidality, a younger age at onset, a longer duration of illness, higher rates of personal and familial depression, concomitant alcohol or sedative-hypnotic abuse, neuropsychiatric abnormalities, and poorer outcome; more frequently associated with cortisol nonsuppression; and less likely to respond adequately to lithium but perhaps more likely to respond to ECT or anticonvulsants.Substantial evidence suggests that dysphoric mania may be a distinct affective state. Contrary evidence, however, suggests that dysphoric mania may be a form of typical mania, a stage-related or severe form of mania, or a transitional state between mania and depression. Because the evidence may be inconsistent because of varying definitions of dysphoric mania among studies, the authors propose preliminary operational diagnostic criteria for the future study of dysphoric mania.
Persistent social maladjustment in bulimia: a 1-year follow-up
Authors: D K Norman, D B Herzog
Journal: American Journal of Psychiatry (1984)

A clinical sample of 40 bulimic women demonstrated more social maladjustment than did normal women, alcoholic women, and schizophrenic women on the social adjustment scale both at the time of evaluation and at 1-year follow-up.
THU0292 Risk Factors Associated with Cranial Ischemic Complications in Patients with Biopsy-Proven Giant Cell Arteritis
Authors: O.M. Olivas, M. Martin, M. Galindo, I. Mateo, P.E. Carreira
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Giant cell arteritis (GCA) is the most frequent vasculitis diagnosed in people over 50 years. Involvement of branches from the internal carotid and vertebral arteries could cause cranial ischemic complications (CIC), as visual loss or ischemic stroke, leading to severe disability. Low inflammatory response, lack of systemic symptoms and traditional cardiovascular risk factors have been suggested as independent risk factors for CIC. It has been also described that previous use of low-dose aspirin might prevent CIC events, although the evidence in this field is scarce <h3>Objectives</h3> To analyze the differences in clinical presentation of patients with biopsy-proven GCA who develop or not CIC, and to evaluate the potential protective effect of pre-treatment with aspirin on CIC development <h3>Methods</h3> Patients with biopsy-proven GCA diagnosed at a single University Hospital between 1992 and 2014 were selected. Demographic and clinical characteristics at GCA diagnosis, and previous cardiovascular risk factors and treatments were obtained from the charts. CIC was defined as: 1) visual loss, attributable to anterior ischemic optic neuropathy or retinal arterial occlusion, and 2) ischemic stroke, occurred at diagnosis or within 4 weeks after. Comparisons between patients with or without CIC were done by bivariate and multivariate binary logistic regression analysis. Statistical significance was defined as p&lt;0.05 <h3>Results</h3> The group included 120 patients, 68.3% f, 31.7% m, mean age at GCA diagnosis 77,85±6,79 y. Twenty seven (22,5%) presented with CIC: 16 patients suffered visual loss, 11 had a stroke and 2 had both. Comparative analysis between patients with and without CIC is shown in table 1. In univariate analysis, the presence of fever was less frequent in patients with CIC, but ESR, CRP and haemoglobin levels were similar in both groups. Statin use, but not other cardiovascular risk factors or treatments, was significantly more frequent in patients with CIC. Previous aspirin or anticoagulant use was not different between patients with or without CIC. These results were confirmed in multivariate analysis. <h3>Conclusions</h3> In our series of biopsy-proven GCA patients, previous use of aspirin is not associated with less incidence of CIC. Previous use of statins, perhaps as a surrogate marker of cardiovascular risk, is associated with the development of CIC in our patients <h3>References</h3> Nesher G, Berkun Y, et. al. Medicine (Baltimore). 2004 Mar;83(2):114-22 Martínez-Taboada VM, Lόpez-Hoyos M,et al. Autoimmun Rev. 2014 Aug;13(8):788-94. <h3>Disclosure of Interest</h3> None declared
Experiences of giving oseltamivir to school children during the 2009 influenza A(H1N1) pandemic
Authors: J Giesecke
Journal: Eurosurveillance (2010)

Preview this article: Experiences of giving oseltamivir to school children during the 2009 influenza A(H1N1) pandemic, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/19/art19570-en-1.gif
Animal↔Man Cancer Probes Continue
Authors: G L Van Hoosier, W Stenback, S C Dunn, E J Macdonald, M C Macdonald, H G Taylor, J J Trentin
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0204 Serum Levels of Vascular Markers Reflect Disease Severity and Stage in Systemic Sclerosis
Authors: M. Cossu, R. Andracco, A. Santaniello, M. Caronni, M. Marchini, A. Severino, T.R. Radstake, L. Beretta
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Vasculopathy is one of the cardinal feature of systemic sclerosis (SSc) that can be observed in every patients from the earliest stages of the disease. Abnormalities in circulating angiogenetic factors and endothelial dysfunction markers in patients at different stages of the disease that include early or non-fibrotic (pre-fibrotic) subjects have not thoroughly described so far. <h3>Objectives</h3> To characterize vasculopathy in SSc patients through the determination of 7 selected vascular biomarkers in sera from a large cohort of patients with well defined and distinct clinical characteristics. <h3>Methods</h3> Sera from 224 subjects were obtained and concentrations of Angiopoietin 2, CXCL-16, E-Selectin, ICAM-1, IL-8, VCAM-1, VEGF were determined by a Luminex commercial assay. Subjects included 43 healthy controls (HC), 47 early systemic sclerosis patients (EaSSc) according to LeRoy and Medsger criteria (Raynaud9s phenomenon + abnormal capillaroscopy patterns and/or SSc-specific antibodies without other signs and symptoms of disease), 48 definitive SSc patients (defSSc) according to the 2013 ACR/EULAR criteria without skin fibrosis, 51 limited cutaneous (lcSSc) and 35 diffuse cutaneous (dcSSc) subjects. <h3>Results</h3> The four groups of patients showed well-distinct clinical and laboratory characteristics with a linear trend of decrease in FVC and DLco % predicted levels from EaSSc to defSSc to lcSSc and to dcSSc patients, and a linear trend of increase in CRP, ESR, gamamglobulin serum levels as well as the prevalence of lung fibrosis on the other way around. Serum concentrations of the studied analytes are reported in the table; for most vascular factors a characteristics linear trend (ANOVA polynomial test for trend &lt;0.01) could be observed with the lowest level in HC and a gradual increase that reflects the severity if the disease. <h3>Conclusions</h3> Our study demonstrate, for the first time, that circulating levels of vascular involvement start to increase in SSc patients from the earlies stages of the disease when clinical and laboratory findings of advanced disease cannot yet be detected. These abnormalities progress in parallel with the appraisal of the first sclerodermatous manifestation in defSSc and steadly increase with the onset of fibrotic manifestations. <h3>Acknowledgements</h3> The present work was financed by a grant from GILS (Gruppo Italiano per la Lotta alla Sclerodermia), theme "La diagnosi precoce della sclerodermia". <h3>Disclosure of Interest</h3> None declared
Focal intrasplenic extramedullary hematopoiesis mimicking lymphoma: diagnosis made using liver-spleen scintigraphy.
Authors: LAURA GELLETT, MICHAEL WILLIAMS, GILLIAN VIVIAN
Journal: Clinical Nuclear Medicine (2001)

GELLETT, LAURA R. F.R.C.R.; WILLIAMS, MICHAEL P. F.R.C.R.; VIVIAN, GILLIAN C. F.R.C.R. Author Information
Diabetes mellitus and cancer.
Authors: E P Kamysheva, I G Abelevich, N N Andriukhina, E I Panova, N Iu Blokhina
Journal: BMJ (1970)

There is evidence on infrequent cases of combined occurrence of cancer and diabetes mellitus (DM). The latter is likely to inhibit malignant growth (W. Rhomberg, G. Jorns, M. A. Kunitsina) as shown by reduced number of metastases and recurrences, especially in noninsulin-dependent DM, longer survival. Presence of cancer, in its turn, diminishes DM manifestations. Radical removal of the tumor promoted rapid DM decompensation. Cancer prognosis in DM presence is dependent on the anatomo-morphological pattern of the lesion and DM type.
Abdominal Surgery
Authors: Claude E. Welch
Journal: New England Journal of Medicine (1975)

THE last report on this subject in the Journal was made approximately three years ago.1 Since that time major contributions include studies on the effects of parietal-cell vagotomy for duodenal ulcer, the increasing use of endoscopy for diagnosis and polypectomy, and the extension of radiologic technics of diagnosis and therapy. Important trends and representative papers that have appeared in the last triennium are considered. Because of space constraints, abstracts are brief, so that this summary must serve as a guide to further reading.Lower Esophagus and Esophageal HiatusReflux EsophagitisRandolph et al. carried out Nissen fundoplications on 31 infants . . .
Fluphenazine decanoate and tardive dyskinesia: a possible association
Authors: J G Csernansky, K Grabowski, J Cervantes, J Kaplan, J A Yesavage
Journal: American Journal of Psychiatry (1981)

The authors examined the charts of 22 outpatients who had received intramuscular fluphenazine decanoate and oral fluphenazine hydrochloride to assess the incidence of tardive dyskinesia. The severity of tardive dyskinesia was assessed with the Abnormal Involuntary Movement Scale (AIMS). Both the total dose and average daily dose of fluphenazine decanoate correlated significantly with high AIMS scores. There were also significant correlations of AIMS scores with total dose of antiparkinsonian medication and total dose of other neuroleptics. Total dose of antiparkinsonian medication correlated with total dose of fluphenazine decanoate. The authors discuss the clinical and physiological implications of these correlations.
Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer
Authors: Bomi Kim, Changkyu Lee, Eun Seong Lee, Beom Soo Shin, Yu Seok Youn
Journal: Asian Journal of Pharmaceutical Sciences (2016)

Albumin nanoparticles are considered to be an effective way to load water-insoluble anticancer drugs and target tumors via the gp60-mediated pathway. Herein, we fabricated an albumin nanoparticle formulation for co-loading paclitaxel (PTX) and curcumin (CCM), both of which have prominent anticancer efficacy, via nanoparticle albumin-bound (NabTM) technology using high-pressure homogenization. The PTX/CCM co-bound albumin nanoparticles (PTX/CCM Alb-NPs) had a slightly greater particle size of ~250 nm than that of plain PTX Alb-NPs and CCM Alb-NPs (~234 and ~134 nm, respectively), with spherical surface morphology and stable size maintenance. However, the zeta potential of PTX/CCM Alb-NPs (ca. −30 mV) was not significantly different from that of PTX or CCM Alb-NPs. The loaded PTX and CCM were released gradually from the PTX/CCM Alb-NPs over ~24 h (97.7 ± 1.7% and 76.2 ± 0.5%, respectively). Furthermore, PTX/CCM Alb-NPs appeared to be efficiently internalized into Mia Paca-2 cells and exhibited a 71% increased IC50 versus PTX Alb-NPs in terms of cytotoxicity to Mia Paca-2 cells. These results suggest that PTX/CCM Alb-NPs are a new potential anticancer agent for combination therapy.
Lung Cancer: Leading Cause of Cancer Deaths in Louisiana White Females
Journal: JNCI Journal of the National Cancer Institute (1984)

Lung Cancer: Leading Cause of Cancer Deaths in Louisiana White Females JNCI: Journal of the National Cancer Institute, Volume 72, Issue 1, January 1984, Pages 1–2, https://doi.org/10.1093/jnci/72.1.1 Published: 01 January 1984
Reductions in insurance for mental disorders: adverse selection, moral hazard, and consumer demand
Authors: S S Sharfstein, C A Taube
Journal: American Journal of Psychiatry (1982)

Coverage for mental illness has been sharply reduced in the Federal Employees Health Benefits Program (FEHBP), especially in the largest of the participating plans, the Blue Cross and Blue Shield plan. The authors examine the role of adverse selection (accumulation of high-risk consumers within a given plan), moral hazard (demand for services for illness depending in part on the price of the services), and lack of overt consumer demand in the current trend. They point out the critical need for psychiatry to develop more effective approaches to public education on the nature of mental illness and its treatment. If the recent major cutbacks in the FEHBP prevail, this kind of restriction is likely to become the prevailing mode of mental illness coverage under private health insurance.
Case 72-1962
Authors: Marshall K. Bartlett, Austin L. Vickery
Journal: New England Journal of Medicine (1962)

Presentation of CaseA twenty-six-year-old married woman was referred to the hospital because of pain in the right upper quadrant.Two days before admission, after experiencing mild dysuria for a week, the patient was awakened by the sudden onset of sharp pain in the right upper quadrant, with radiation toward the pubis and the middle of the back. The pain was continuous, with crampy peaks of increased severity, and was partially relieved by morphine. She was moderately nauseated, but did not vomit. Because of increase in the abdominal pain she was admitted to another hospital, where physical examination disclosed marked . . .
Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells
Authors: R. Tancredi, V. Fotia, F. Moccia, V. Rosti, C. Porta, M.G. Della Porta, L. Beltrame, G.A. Da Prada, A. Zambelli, A. Riccardi
Journal: Annals of Oncology (2015)
An Alkylating Agent for Multiple Myeloma
Authors: B S BLUMBERG, H J ALTER, S VISNICH
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case 15-1982
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely
Journal: New England Journal of Medicine (1982)

Presentation of Case A 55-year-old man was admitted to the hospital because of splenomegaly. He was in good health until six months earlier, when he began to experience easy fatigability, anorexia, and aches in the buttocks and thighs. Three months before admission he began to have pain in the left upper abdominal quadrant, which persisted and was unrelated to meals. One month before entry leg weakness developed, the abdominal pain worsened, and night sweats occurred. His physician found that the spleen was enlarged. A 99mTc sulfur colloid liver-spleen scan (Fig. 1) showed that the liver was at the upper limit . . .